Pheast Therapeutics Presents Preclinical Data on PHST677, a
REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) — Pheast Therapeutics, a clinical-stage biotechnology company advancing macrophage-directed immunotherapies…
Browsing Tag